Pfizer Reports Positive Phase 3 Results for Vitiligo Treatment Litfulo
Pfizer (PFE) announced positive results from two phase 3 trials of its drug ritlecitinib, marketed as Litfulo. The data showed significant improvements in facial and total body repigmentation among patients with vitiligo after one year of treatment. The findings support the potential efficacy of Litfulo for treating this chronic skin condition characterized by loss of pigment. These results could bolster Pfizer's dermatology portfolio, which has been a focus area following its spin-off from Upjohn in 2023.
Tickers: $PFE
Topics: clinical trial results Litfulo ritlecitinib vitiligo